TABLE 4.
Anti-HCV activity in the presence of human serum binding proteinsa
| Compound | 10% FBS (EC50 [pM]) | 10% FBS + AAG |
40% HS |
||
|---|---|---|---|---|---|
| EC50 (pM) | Mean fold changeb | EC50 (pM) | Mean fold changeb | ||
| Samatasvir | 3.0 ± 0 | 6.0 ± 0 | 2.7 ± 0.3 | 25.0 ± 1.0 | 10.4 ± 0.2 |
| Daclatasvir | 14.0 ± 3.0 | 119 ± 21.0 | 9.4 ± 1.1 | 33.5 ± 6.0 | 2.6 ± 0.5 |
a
Values are the mean ± standard deviation of the results of 3 independent experiments.
b
A fold change was calculated for each experiment and a mean fold change ± standard deviation was calculated with these 3 values.